Company intelligence / Profile preview

Adrestia Therapeutics

Cambridge, England, United Kingdom

Ownership: Public · INSM
Employees: ~20
Development stage: Other

Overview

Adrestia’s synthetic rescue platform can identify novel therapeutic targets and modalities for genetic diseases lacking direct druggable mutations; clinical candidate pipeline not yet initiated; collaborations advancing preclinical discovery in several diseases

Therapeutic areas: NeurologyRare DiseasesCardiovascular
Modalities: Small moleculeOligonucleotideGene therapy
Industry: Biotech

Partnerships

GSK (target discovery alliance)University College London (Huntington's disease research collaboration)Ataxia-telangiectasia (AT) Children’s Project, AT Society, Action for AT (research consortium)

Beyond the preview

Go deeper on Adrestia Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adrestia Therapeutics.

Explore the full profile